Pre-made Cantuzumab benchmark antibody ( Whole mAb ADC, anti-MUC1 therapeutic antibody, Anti-ADMCKD/ADMCKD1/ADTKD2/CA 15-3/CD227/Ca15-3/EMA/H23AG/KL-6/MAM6/MCD/MCKD/MCKD1/SEC/X/ZD/PEM/PEMT/PUM Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Cantuzumab biosimilar, Whole mAb ADC, Anti-MUC1 Antibody: Anti-ADMCKD/ADMCKD1/ADTKD2/CA 15-3/CD227/Ca15-3/EMA/H23AG/KL-6/MAM6/MCD/MCKD/MCKD1/SEC/X/ZD/PEM/PEMT/PUM therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cantuzumab is a monoclonal antibody designed for the treatment of cancers. Also known as huC242 it binds the CanAg antigen.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-092-1mg	1mg	Inquiry
GMP-Bios-ab-092-10mg	10mg	Inquiry
GMP-Bios-ab-092-100mg	100mg	Inquiry
GMP-Bios-ab-092-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Cantuzumab biosimilar, Whole mAb ADC, Anti-MUC1 Antibody: Anti-ADMCKD/ADMCKD1/ADTKD2/CA 15-3/CD227/Ca15-3/EMA/H23AG/KL-6/MAM6/MCD/MCKD/MCKD1/SEC/X/ZD/PEM/PEMT/PUM therapeutic antibody
INN Name	Cantuzumab
Target	MUC1
Format	Whole mAb ADC
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2003
Year Recommended	2004
Companies	ImmunoGen;GlaxoSmithKline
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Gastric cancer;Solid tumours
Development Tech	na